Serum magnesium levels in healthy dogs submitted to the administration of cisplatin with fluid therapy

Main Article Content

Carlos Alfredo Calpa Oliva
Carlos Roberto Daleck
João Humberto Teotônio de Castro
Andrigo Barboza de Nardi

Abstract

Cisplatin is an antineoplastic drug that is used to treat carcinomas and osteosarcomas in dogs. However, it can cause kidney damage which in turn leads to the loss of electrolytes. Concentration of magnesium was evaluated in the blood serum of eight dogs that had undergone therapy with cisplatin. The dogs were divided into two groups. Group 1 was supply with cisplatin (70 mg/m2, iv) and to prevent nephrotoxcity, saline solution at 0.9% was administered (25 ml/kg/hour, iv in three hours). The animals in Group 2 were not supplied with cisplatin. There was no significant difference (P < 0.05) between the two groups and the results obtained indicated that the protocol used for Group 1 did not cause changes in the serum concentrations of magnesium. Therefore, it can be concluded that the administration of cisplatin does not cause variations if it is combined with the fluid therapy.
Keywords:
CISPLATIN FLUID THERAPY CHEMOTHERAPY MAGNESIUM ELECTROLYTES

Article Details